Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | ||||||
{[ item.p_purity ]} | {[ item.pr_size ]} | Inquiry |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]} |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]} | {[ item.pr_usastock ]} | in stock Inquiry - | {[ item.pr_chinastock ]} | {[ item.pr_remark ]} in stock Inquiry - | Login | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
Seungil Kim ; Kamil W. Nowicki ; Keishi Kohyama , et al. Biomacromolecules,2024,25(8):4879-4890. DOI: 10.1021/acs.biomac.4c00321 PubMed ID: 39001820
More
Abstract: Cerebral aneurysms are a source of neurological morbidity and mortality, most often as a result of rupture. The most common approach for treating aneurysms involves endovascular embolization using nonbiodegradable medical devices, such as coils. However, the need for retreatment due to the recanalization of coil-treated aneurysms highlights the importance of exploring alternative solutions. In this study, we propose an injectable extracellular matrix derived embolic formed in situ by Michael addition of gelatin-thiol (Gel-SH) and hyaluronic acid vinyl (HA-VS) that may be delivered with a therapeutic agent (here, RADA-SP) to fill and remodel aneurysmal tissue without leaving behind permanent foreign bodies. The injectable embolic material demonstrated rapid gelation under physiological conditions, forming a highly porous structure and allowing for cellular infiltration. The injectable embolic exhibited thrombogenic behavior in vitro that was comparable to that of alginate injectables. Furthermore, in vivo studies in a murine carotid aneurysm model demonstrated the successful embolization of a saccular aneurysm and extensive cellular infiltration both with and without RADA-SP at 3 weeks, with some evidence of increased vascular or fibrosis markers with RADA-SP incorporation. The results indicate that the developed embolic has inherent potential for acutely filling cerebrovascular aneurysms and encouraging the cellular infiltration that would be necessary for stable, chronic remodeling.
Purchased from AmBeed: 15441-06-2
CAS No. : | 15441-06-2 | MDL No. : | MFCD00128218 |
Formula : | C8H14O4S2 | Boiling Point : | No data available |
Linear Structure Formula : | - | InChI Key : | OSZKBWPMEPEYFU-UHFFFAOYSA-N |
M.W : | 238.32 | Pubchem ID : | 84913 |
Synonyms : |
|
Signal Word: | Warning | Class: | |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
[ 13327-56-5 ]
Ethyl 3-(methylthio)propanoate
Similarity: 0.68
[ 30374-01-7 ]
6-Methylheptyl 3-mercaptopropanoate
Similarity: 0.64
[ 90030-48-1 ]
Sodium 3-methoxy-3-oxopropane-1-sulfinate
Similarity: 0.56
[ 13327-56-5 ]
Ethyl 3-(methylthio)propanoate
Similarity: 0.68
[ 30374-01-7 ]
6-Methylheptyl 3-mercaptopropanoate
Similarity: 0.64
[ 90030-48-1 ]
Sodium 3-methoxy-3-oxopropane-1-sulfinate
Similarity: 0.56
[ 13327-56-5 ]
Ethyl 3-(methylthio)propanoate
Similarity: 0.68